Larimar Completes Rolling BLA for Nomlabofusp; $128.7M Cash Runs to Late Q2 2027
LRMR sits 32% above its 52-week low of $1.915.
Summary
Larimar has finished its rolling BLA for nomlabofusp in Friedreich's ataxia and disclosed roughly $128.7 million of cash at September 30, enough to fund operations into late Q2 2027 — just as an FDA approval decision is expected mid-2027.
Key Events · Product Development and Regulatory · LRMR
-
Rolling BLA Submission Completed
Larimar completed its rolling Biologics License Application to FDA seeking accelerated approval of nomlabofusp for Friedreich's ataxia, using skin frataxin as a proposed novel surrogate endpoint.
-
Cash of $128.7M, Runway to Late Q2 2027
Preliminary, unaudited cash, cash equivalents and marketable securities were approximately $128.7 million as of September 30, 2026, with projected runway into late Q2 2027.
-
Approval Decision Expected Mid-2027
Company-guided milestones: BLA acceptance early 2027, open-label safety update Q1 2027, U.S. approval mid-2027 and launch targeted Q3 2027, contingent on FDA approval.
-
Confirmatory Phase 3 Still Enrolling
FORWARD-FA, the global double-blind placebo-controlled Phase 3, is enrolling 100-150 ambulatory participants ages 2 to 40 over 18 months of treatment.
Analysis · LRMR · Life Sciences
The biggest regulatory step yet for nomlabofusp, Larimar's only clinical asset, is now complete: the rolling BLA moves the program into FDA review, with a potential mid-2027 approval and Q3 2027 launch. The filing also puts a number on the balance sheet for the first time since the going-concern warning in the August 10-Q, showing about $128.7 million at September 30 and runway into late Q2 2027. Because that runway ends right around the expected approval decision, the company likely needs to raise capital before or shortly after a decision unless a partnership or voucher monetization fills the gap. Completion of the submission does not assure acceptance for filing or approval, and FDA still has to agree that skin frataxin is an acceptable surrogate endpoint.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LRMR was trading at $2.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $262.8M. The 52-week trading range was $1.92 to $6.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.